Enhancing patient outcomes with iGlarLixi – Addressing key moments in the T2DM journey

shutterstock_2381164841 - image for home page

Each new stage of the patient journey with T2DM presents fresh opportunities for the clinician to innovate with therapies such as basal insulin/GLP-1RA fixed ratio combinations

Learning objectives

You will learn:

  • How changes in β-cell function and mass influence glucose tolerance and insulin secretion across the disease continuum of type 2 diabetes (T2DM), and the importance of preserving pancreatic function
  • How fixed-ratio combinations (FRCs) of basal insulin plus glucagon-like peptide-1 receptor agonists can provide simpler, effective alternatives to complex T2DM treatment regimens
  • Currently available options for insulin advancement in the patient with T2DM and with suboptimal glucose control on their current treatment regimen
  • Clinical evidence supporting the efficacy and safety of iGlarLixi for suboptimally controlled T2DM using oral antidiabetic drugs with or without basal insulin or premixed insulin.

To access this module, please register or login: